Hims & Hers is transforming telehealth with personalized medications, rapid subscription growth, and strong financials, ...

Hims & Hers Health (NYSE: HIMS) stock is on a downward trend on both macro trends and news about GLP-1s. But this is still a ...

Hims stock skidded Thursday after the FDA determined Eli Lilly's tirzepatide — which sells as a weight-loss drug — is no ...

The Short discusses a 15% drop in Hims & Hers stock following an FDA announcement ending the shortage of Eli Lilly's weight ...

Hims & Hers faces regulatory hurdles but shows strong business growth. Find out why HIMS stock is a "Hold" despite setbacks ...

Craig Hettenbach, an analyst from Morgan Stanley, maintained the Buy rating on Hims & Hers Health (HIMS – Research Report). The associated ...

CNBC’s Jim Cramer suggested on Tuesday that NVIDIA Corp. (NASDAQ:NVDA) may have reached a key turning point after the stock ...

HIMS is on track for its worst single-session decline since Nov. 14, when Amazon.com (AMZN) entered the telehealth services ...

Analyst Allen Lutz of Bank of America Securities maintained a Sell rating on Hims & Hers Health (HIMS – Research Report), retaining the ...

In terms of liquidity and interest, the mean open interest for Hims & Hers Health options trades today is 3348.53 with a ...

For most Americans, weight is more than just a number. It shapes our health, our mood, our confidence, our spending, and the ...

Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, ...